Essential Resources

Provider Information

Patient Information

From Our Sponsors

Essential Resources for the Treatment of Congenital Adrenal Hyperplasia
FDA Accepts 2 NDAs, Grants Priority Review for Crinecerfont for Pediatric, Adult CAH

FDA Accepts 2 NDAs, Grants Priority Review for Crinecerfont for Pediatric, Adult CAH

Neurocrine Biosciences made the announcement and said, if approved in December, crinecerfont will be the first new treatment and treatment approach to CAH in 70 years.

Read More →
Management of Congenital Adrenal Hyperplasia in Adults: Challenges with Standard of Care / image credit glucocorticoids  ©Andrii/stock.adobe.com

Management of Congenital Adrenal Hyperplasia in Adults: Challenges with Standard of Care

The standard of care for congenital adrenal hyperplasia has not changed in more than 60 years nor have the challenges it presents been overcome.

Read More →
Emerging Therapies in Management of Congenital Adrenal Hyperplasia /©Charisma Art Studio/stock.adoe.com via AI

Emerging Therapies in Management of Congenital Adrenal Hyperplasia

Investigational treatments for congenital adrenal hyperplasia are focused on new ways to manage symptoms without the need for supraphysiologic doses of glucocorticoids.

Read More →
Androgen Management in CAH: A Primer  / Image credit kidney/adrenal gland ©Sebastian Kaulitzki/stock.adobe.com

Androgen Management in Congenital Adrenal Hyperplasia: A Primer

Current therapies fall short of quelling the long-term exposure to and adverse effects of excessive androgen levels experienced by adults with CAH.

Read More →
©Sebastian Kaulitzki/stock.adobe.com

Neurocrine Biosciences CAHtalyst Adult Phase 3 Clinical Trial Meets All Endpoints in Congenital Adrenal Hyperplasia, Published in NEJM

The registrational clinical trial met all endpoints related to androgen reduction and glucocorticoid dose reduction while maintaining androgen control.

Read More →

FDA Grants Breakthrough Therapy Designation for Oral Congenital Adrenal Hyperplasia Medication

Crinecerfont was granted FDA breakthrough therapy designation for the treatment of congenital adrenal hyperplasia.

Read More →
© 2024 MJH Life Sciences

All rights reserved.